© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.
February 27, 2021
Article
Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.
December 12, 2020
Article
Boehringer Ingelheim's argument hinges on how "strength" of formulation is defined in regulatory language.
October 31, 2020
Article
The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.
September 05, 2020
Article